| GTO ID | GTC3021 |
| Trial ID | NCT05359354 |
| Disease | Solid Tumor |
| Therapy | mRNA vaccine |
| Treatment | PGV002 |
| Co-treatment | PD-1 |
| Phase | Not Applicable |
| Recruitment status | Recruiting |
| Title | A Dose-Escalation and Dose-Expansion Study Evaluating the Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Solid Tumors |
| Year | 2022 |
| Country | China |
| Company sponsor | YueJuan Cheng |
| Other ID(s) | XKY-1007 |
| Cohort 1 | |||||||||
|
|||||||||